Baltimore startup Vita Therapeutics raises $31M to advance treatment for genetic diseases
Baltimore's Vita Therapeutics announced the completion of a $31 million series B funding round on Wednesday, propelling the cell therapy company toward a clinical trial and the development of new treatments for rare diseases.
The round, led by Cambrian BioPharma and Solve FSHD, will pay for the studies Vita needs for a human clinical trial for VTA-100, a treatment for a genetic disease called limb-girdle muscular dystrophy that weakens the muscles of a patient's arms and legs. CEO Douglas Falk …
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Matt Hooke Source Type: news
More News: Biotechnology | Clinical Trials | Funding | Genetics | Health Management | Muscular Dystrophy | Rare Diseases | Reflex Sympathetic Dystrophy | Study